8,134 Shares in Guardant Health, Inc. (NASDAQ:GH) Purchased by Sherbrooke Park Advisers LLC

Sherbrooke Park Advisers LLC acquired a new position in shares of Guardant Health, Inc. (NASDAQ:GH) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 8,134 shares of the company’s stock, valued at approximately $248,000.

A number of other hedge funds have also modified their holdings of the company. NewEdge Advisors LLC grew its holdings in shares of Guardant Health by 13.5% during the fourth quarter. NewEdge Advisors LLC now owns 1,929 shares of the company’s stock worth $59,000 after buying an additional 230 shares in the last quarter. Summit Investment Advisors Inc. grew its holdings in shares of Guardant Health by 3.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 12,346 shares of the company’s stock worth $377,000 after buying an additional 391 shares in the last quarter. Arizona State Retirement System grew its holdings in shares of Guardant Health by 1.1% during the fourth quarter. Arizona State Retirement System now owns 35,639 shares of the company’s stock worth $1,089,000 after buying an additional 403 shares in the last quarter. Jones Financial Companies Lllp grew its holdings in shares of Guardant Health by 43.5% during the fourth quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company’s stock worth $82,000 after buying an additional 817 shares in the last quarter. Finally, R Squared Ltd bought a new position in shares of Guardant Health during the fourth quarter worth about $26,000. 92.60% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CEO Amirali Talasaz sold 106,784 shares of Guardant Health stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $49.01, for a total transaction of $5,233,483.84. Following the completion of the sale, the chief executive officer now directly owns 2,202,672 shares of the company’s stock, valued at approximately $107,952,954.72. This trade represents a 4.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last ninety days, insiders sold 107,132 shares of company stock valued at $5,249,355. Insiders own 6.10% of the company’s stock.

Guardant Health Trading Down 1.1%

NASDAQ:GH opened at $40.24 on Tuesday. The stock has a market cap of $4.99 billion, a P/E ratio of -11.30 and a beta of 1.49. The stock has a 50 day simple moving average of $43.75 and a 200 day simple moving average of $39.88. Guardant Health, Inc. has a 1-year low of $20.14 and a 1-year high of $52.92.

Guardant Health (NASDAQ:GH) last released its quarterly earnings results on Wednesday, April 30th. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.08. The business had revenue of $203.47 million during the quarter, compared to analysts’ expectations of $189.91 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The firm’s revenue for the quarter was up 20.8% compared to the same quarter last year. During the same period last year, the firm posted ($0.46) EPS. As a group, sell-side analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current year.

Wall Street Analysts Forecast Growth

GH has been the subject of a number of research reports. UBS Group increased their price objective on Guardant Health from $65.00 to $70.00 and gave the stock a “buy” rating in a report on Thursday, May 1st. Mizuho began coverage on Guardant Health in a research note on Thursday, April 10th. They issued an “outperform” rating and a $55.00 price target for the company. Canaccord Genuity Group raised their price target on Guardant Health from $60.00 to $65.00 and gave the company a “buy” rating in a research note on Thursday, May 1st. TD Securities raised their price target on Guardant Health from $56.00 to $60.00 and gave the company a “buy” rating in a research note on Thursday, May 1st. Finally, JPMorgan Chase & Co. raised their price target on Guardant Health from $50.00 to $55.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. Twenty-one investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Guardant Health currently has an average rating of “Buy” and an average target price of $52.32.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.